Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection
Details : Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Product Name : Tirofiban Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2023
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenecteplase,Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : CSPC Pharmaceutical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 03, 2022
Lead Product(s) : Tenecteplase,Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : CSPC Pharmaceutical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
Correvio Partners with Hong Kong Teson Pharma Limited
Details : The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $3.0 million
October 03, 2020
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
Lead Product(s) : Tirofiban,Aspirin,Clopidogrel
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves...
Product Name : Aggrastat
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Tirofiban,Aspirin,Clopidogrel
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT
Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...
Product Name : Aggrastat
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2013
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban,Clopidogrel,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2012
Lead Product(s) : Tirofiban,Clopidogrel,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : SCRI Development Innovations, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2012
Lead Product(s) : Tirofiban,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : SCRI Development Innovations, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable